Search
SOLACI Congress
HomeFile

File

View Category
Structural heart disease

Post-dilation in TAVI associated to more stroke and more paravalvular regurgitation

Courtesy of Dr. Carlos Fava. Moderate/severe paravalvular regurgitation (PVR) after TAVR is present in 10%-14% of all cases, according to different...
solaci -
Learn More
Chronic Ischemic cardiopathy

New generation DES present better results in vein grafts than older DES and BMS

There is little information comparing contemporary drug eluting stents (DES)  against bare metal stents (BMS), for PCI in...
solaci -
Learn More
Chronic Ischemic cardiopathy

BVS: Controvertial Scaffold

Courtesy of Dr. Agustín Vecchia. The advent of resorbable vascular scaffolds (BVS) generated high expectations among interventionists because...
solaci -
Learn More
Femoral

Critical ischemia in the lower limbs: Frequent Readmissions show the magnitude of this problem

Readmissions at 6 months in patients with critical ischemia in the lower limbs occur in about 50% of...
solaci -
Learn More
Acute coronary syndromes

Prior assistance with Impella 2.5 lowers 30-day mortality in cardiogenic shock due to unprotected left main coronary artery lesion

Courtesy of Dr. Carlos Fava. The prevalence of cardiogenic shock in acute myocardial infarction (MI) is 7%-10%, and it is associated...
solaci -
Learn More
Structural heart disease

Transcatheter valve replacement in the bicuspid valve is increasingly performed, but challenges remain

As experience increases, transcatheter aortic valve replacement (TAVR) has expanded to different populations and anatomies. This study sought to...
solaci -
Learn More
Chronic Ischemic cardiopathy

Less volume, more mortality: should we be concerned?

Courtesy of Dr. Agustín Vecchia. In general, guidelines recommend a number of procedures a year for operators to maintain...
solaci -
Learn More
Coronary disease

CTO in patients with acute myocardial infarction increases long term mortality

Courtesy of Dr. Carlos Fava. It has been proved that in a setting of acute myocardial infarction with multivessel...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Dr. Omar Tupayachi - 0
Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Dr. Juan Manuel Pérez - 0
Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....

TAVR in Pure Native Aortic Regurgitation: Are Dedicated Devices Truly Superior?

Dr. Juan Manuel Pérez - 0
This systematic meta-analysis assessed the efficacy and safety of transcatheter aortic valve replacement (TAVR) in patients with pure native aortic regurgitation. The emergence of...

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy